[1]徐露露,张 钿,陈井婵,等.医保战略性购买对医药企业创新的影响研究[J].卫生经济研究,2023,40(12):7-10.
　XU Lulu,ZHANG Tian,CHEN Jingchan,et al.Study on the Impact of Strategic Purchase of Medical Insurance on Innovation of Pharmaceutical Enterprises[J].Journal Press of Health Economics Research,2023,40(12):7-10.
点击复制

医保战略性购买对医药企业创新的影响研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
40
期数:
2023年12期
页码:
7-10
栏目:
医疗保障
出版日期:
2023-11-30

文章信息/Info

Title:
Study on the Impact of Strategic Purchase of Medical Insurance on Innovation of Pharmaceutical Enterprises
作者:
徐露露1; 张 钿1; 陈井婵1; 禄晓龙1; 2; 3
1.贵州医科大学医药卫生管理学院，贵州 贵阳 550025
2.贵州医科大学医药经济管理研究中心，贵州 贵阳 550025
3.贵州省健康发展研究中心，贵州 贵阳 550025
Author(s):
XU Lulu;  ZHANG Tian;  CHEN Jingchan;  LU Xiaolong
School of Medicine and Health Management, Guizhou Medical University, Guiyang Guizhou 550025, China
关键词:
医保战略性购买; 医药企业; 医保支付政策; 集中带量采购
Keywords:
strategic purchase of medical insurance;  pharmaceutical enterprises;  medical insurance payment policies;  centralized volume-based procurement
分类号:
R197；F840.684
文献标志码:
A
摘要:
目的：分析药品集中带量采购政策对医药企业创新的影响，为充分发挥医保战略性购买作用，推动医药企业创新发展提供参考。方法：采用描述性分析方法，分析药品集中带量采购、药品谈判准入、医保支付方式改革对医药企业创新发展的影响。结果：药品集中带量采购政策对促进医药企业创新发展的作用日益突显，医保支付方式改革在平衡医保基金收支与促进医药企业创新之间存在困难，医保药品谈判准入机制在鼓励创新的同时对医保基金的承受力造成了挑战。结论：医保战略性购买能够促进医药企业开展创新，但目前仍存在一些不足，应从完善创新药医保支付体系、药品谈判准入机制和药品集中带量政策入手，进一步发挥医保政策对医药企业的创新促进作用，推动医药企业迈向全面创新之路。
Abstract:
Objective To analyze the impact of centralized volume-based procurement policies on the innovation of pharmaceutical enterprises, and to provide reference for giving full play to the strategic purchasing role of health insurance and promoting the innovative development of pharmaceutical enterprises. Methods Descriptive analysis methods were used to analyze the impact of centralized volume-based procurement of drugs, drug negotiation access, and reform of medical insurance payment methods on the innovative development of pharmaceutical enterprises. Results The role of the policy of centralized volume-based procurement of drugs in promoting the innovative development of pharmaceutical enterprises was increasingly prominent. The reform of medical insurance payment methods faced difficulties in balancing the income and expenditure of medical insurance funds and promoting innovation of pharmaceutical enterprises. The negotiation and access mechanism for medical insurance drugs encouraged innovation, but at the same time challenged the affordability of medical insurance funds. Conclusion Strategic purchasing of medical insurance can promote innovation in pharmaceutical enterprises, but there are still some shortcomings at present. We should start by improving the payment system for innovative medical insurance, the mechanism for drug negotiation and access, and the policy for centralized volume-based procurement of drugs. We need to further leverage the innovation promotion role of medical insurance policies for pharmaceutical enterprises, and promote them towards a path of comprehensive innovation.

参考文献/References:

[1] 李毅仁，路云，卢钰琼，等.帕累托改进:我国医保战略性购买的践行路径[J].卫生经济研究，2020，37（10）：8-11.
[2] 瞿婷婷，解乃琪，易沛.医疗保险支付方式改革与医药费用控制[J].南开经济研究，2019（5）：145-162.
[3] 吴学智，李捷，邓淑娟，等.攀枝花市实施DRGs付费改革对医保患者住院费用的影响分析[J].重庆医学，2021，50（24）：4283-4287.
[4] 曹鑫，阮娴静.基于因子分析法的我国医药企业创新发展能力评价研究[J].中国药房，2020，31（16）：1931-1937.
[5] 国家医保局等八部门.关于印发《深化医疗服务价格改革试点方案》的通知（医保发〔2021〕41号）[EB/OL].（2021-08-31）[2023-04-12].http://www.nhsa.gov.cn/art/2021/8/31/art_104_6542.html.
[6] 小鹿关爱科普.医保支付改革将给药企、医院、患者带来哪些改变?[EB/OL].（2022-01-25）[2023-04-12].https://view.inews.qq.com/k/20220119A07EUZ00?web_channel=wap&openApp=fal se&autoopenapp=ampzkqw&pgv_ref=amp.
[7] 医药慧.北京探索DRG外支付模式,创新药迎准入曙光[EB/OL].（2022-08-02）[2023-04-12].https://mp.weixin.qq.com/s?__biz=MjM5MzU5MzUwNQ==&mid=2652057347&idx=3&sn=432b486 31ae78ff753328a8ea7f08b16&chksm=bd732ecd8a04a7db08cff2a b98eac9eb538f1117bc70fbf69afbfb362a00de658be9c34acba1&sc ene=27.
[8] 医药经济报.医保谈判准入跨越三大难点[EB/OL].（2022-08-24）[2023-05-18]. http://www.yyjjb.com.cn/yyjjb/202208/20220804153 800380_12999.shtml.
[9] 健康国策2050. “突破性治疗”创新药:医保应简化准入/更高阈值予以扶持[EB/OL].（2023-03-29）[2023-04-30]. http://zgyjw.org.cn/news/7503.html.
[10] 凤凰新闻.医保准入助推创新药发展:怎一个“降”字了得[EB/OL].（2021-05-26）[2023-04-30].https://ishare.ifeng.com/c/s/v002BiDqcBwiuSgDdS8NlvqCEqjc8bLK5EcCACK-_PvHKZ--g.

[11] 周若婧，杨照，江滨.国家组织药品带量采购政策的控费效果及其影响因素研究[J].中国卫生政策研究，2022，15（9）：56-63. [12] 谈在祥，范舜.药品“4+7”带量集中采购背景下医药企业的挑战与应对[J].卫生经济研究，2019，36（8）：13-15,19.

相似文献/References:

[1]殷　猛,李　琪,刘霁堂.医药企业电子商务转型的影响因素及策略研究[J].卫生经济研究,2016,(03):25.
[2]谈在祥,范 舜.药品“4+7”带量集中采购背景下医药企业的挑战与应对[J].卫生经济研究,2019,(08):13.
　TAN Zai-xiang,FAN Shun.Challenges and Countermeasures of Pharmaceutical Enterprises under the Background of Centralized Purchasing of Drugs “4+7”[J].Journal Press of Health Economics Research,2019,(12):13.
[3]李 萍,汤少梁.后疫情时代药品集中带量采购政策制约因素与执行路径——基于史密斯政策执行模型[J].卫生经济研究,2021,38(4):32.
　LI Ping,TANG Shao-liang.The Restrictive Factors and Implementation Path of Drug Centralized Quantity Purchase Policy in the Post-epidemic Era——Based on Smith Policy Implementation Model[J].Journal Press of Health Economics Research,2021,38(12):32.
[4]张小娟.全民健康覆盖视角下的分级诊疗制度研究[J].卫生经济研究,2021,38(6):10.
　ZHANG Xiao-juan.Study on Graded Diagnosis and Treatment System from the Perspective of Universal Health Coverage[J].Journal Press of Health Economics Research,2021,38(12):10.

更新日期/Last Update: 2023-11-30